【CPhI 开讲啦】第7期,前赛诺菲巴斯德副总裁Klein博士解读前沿疫苗趋势

摘要: 10月19日,国际公认疫苗学专家米歇尔·克莱因(Michel KLEIN)将线上为您分享疫苗研发的未来发展趋势,报名从速!

10-31 12:03 首页 CPhI制药在线




疫苗是近10年全球增长速度最快的生物制品之一,其增长率的峰值曾达到了近50%。在全球病毒感染性疾病此起彼伏的形势下,免疫疫苗、抗病毒疫苗、抗肿瘤疫苗已成为开发的热点。此外,得益于基因组学、蛋白质组学、免疫学、结构生物学和生物信息学等方面在研究上的显著进步,在未来十年内疫苗更是有望成为人们预防及治疗疾病的最佳选择手段。



讲座主题

The Future of Vaccines


讲座时间

2017.10.19(周四)   15:00-16:30


讲座时长

1.5小时(50分钟主题演讲,40分钟互动问答)


讲座形式

视频直播


演讲嘉宾

Michel KLEIN


温馨提示

全程英文演讲,无中文翻译


演讲嘉宾简介

米歇尔·克莱因(Michel KLEIN)


· 国际公认疫苗学专家

· 25年疫苗研究和开发经验

· 曾任赛诺菲巴斯德副总裁

· BravoVax(武汉)的首席运营官

· 在疫苗学、免疫学、传染病学和生物技术领域的200多家科学出版物上发表过文章


Michel KLEIN is an internationally recognized expert in Vaccinology. He graduated from the Faculty of Medicine and the Institut Pasteur of Paris. He has been a Professor of Immunology at the University of Toronto and has 25 years of experience invaccine research and development. He held the position of Vice President Research at Pasteur Mérieux Connaught and that of Corporate Vice President,Science and Technology, of the Aventis-Pasteur Group (now Sanofi Pasteur) until 2002 when he retired. He then held the position of Chief Executive Officer of the Canadian Network for Vaccines and Immunotherapeutics until 2006. He servedas a member of the EDCTP Partnership Board of the European Union until 2007, Hewas Visiting Professor at the National Health Research Institutes of Taiwan and is today Chief Operating Officer at BravoVax (Wuhan).


He has developed the five-component acellular pertussis vaccine currently on the world market, as well as PIV-3, RSV, influenza virus HIV, and cancer vaccines during his tenureat Sanofi Pasteur and actively contributed to the development of the TaiwaneseH5N1 and EV71 vaccines.


He is the author of more than 200 scientific publications and patents in the fields of vaccinology, immunology,infectious diseases and biotechnology. He is a member of several Boards of Directors and Scientific Advisory Boards. He is a knight in the French order ofthe Légion d’Honneur.


报名渠道

长按识别以下二维码,购买听会券

前50名报名听众可享99元票价(原价199)!!!




上周热门文章精选

《癌症疫苗现在要火了,但当年那个第一个“吃螃蟹”的药企已经不在了》

《六大类帕金森综合征药物概述,仍有巨大开发空间》

《印度药企Gland Pharma到底有何魅力,复星医药愿斥资逾10亿美元》

《木糖醇也是糖 减肥不能靠它》

《FDA松绑仿制药 首款抗癌药物Mvasi获批上市》

《再鼎医药正式登陆纳斯达克,会成为第二个百济神州吗?》

《最新战况!重磅抗癌药物贝伐株单抗竞品的国内研发格局》


来源:CPhI制药在线

声明:本文仅代表作者观点,并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。

客服热线:400 610 1188

投稿邮箱:Kelly.Xiao@ubmsinoexpo.com



想要深入与制药行业的专业人士建立沟通吗?

赶快加入我们的微信社群,与更多行业大咖聊聊那些事儿!

戳下面的阅读原文,更有料
  

首页 - CPhI制药在线 的更多文章: